MARKET

CRL

CRL

Charles Riv Labs Intl Inc
NYSE
252.95
+3.39
+1.36%
After Hours: 252.39 -0.56 -0.22% 17:45 02/27 EST
OPEN
250.55
PREV CLOSE
249.56
HIGH
253.60
LOW
249.04
VOLUME
483.21K
TURNOVER
0
52 WEEK HIGH
253.60
52 WEEK LOW
161.65
MARKET CAP
12.99B
P/E (TTM)
27.42
1D
5D
1M
3M
1Y
5Y
This Insider Has Just Sold Shares In Charles River Laboratories International
Charles River Laboratories International, Inc. Insider sold US$1.0m worth of stock at a price of US$249 per share. In the last year we saw more insider selling of Charles River Laboratories international shares than buying. The company owns 1.2% of Charles river Laboratories International. William Barbo sold shares for 19% of his stake in the company. It's good to see an insider sale of shares at a lower price, but it's not a good sign for shareholders. Charles River Labs International has been bought in the last three months. But the insider selling is a warning sign for investors to watch.
Simply Wall St · 1d ago
Weekly Report: what happened at CRL last week (0219-0223)?
Weekly Report · 1d ago
Charles River Laboratories International (CRL) Price Target Increased by 11.10% to 263.39
NASDAQ · 3d ago
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
NASDAQ · 5d ago
Interesting CRL Put And Call Options For January 2025
NASDAQ · 6d ago
Charles River (CRL) Gains From CRADL Amid Soft Market Scenario
NASDAQ · 6d ago
Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues
Charles River Laboratories International, Inc. (NYSE:CRL) released a solid earnings report last week. The company gained US$55m from unusual items in the last 12 months. Its statutory profits have been distorted by these unusual items. Charles River Laboratories international's profit is expected to be weaker in the next year. We've identified 1 warning sign with Charles River Labs International.
Simply Wall St · 6d ago
Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells
Charles River Laboratories International, Inc. Has entered into an agreement with Pluristyx Inc. The collaboration provides Charles River with broad access to stem cell lines to support development of new therapies. Charles River will distribute a broad catalog of Plurstyx’s ES and iPS cell lines for research.
Barchart · 02/20 07:08
More
About CRL
Charles River Laboratories International, Inc. is a full service, non-clinical contract research company. The Company provides research models required in research and development of new drugs, devices, and therapies. The Company operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment includes the research models, research model services, and research and cells solutions businesses. The DSA segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. The Manufacturing segment includes Microbial Solutions and Biologics Solutions (Biologics).

Webull offers Charles River Lbrtrs ntrntl Inc stock information, including NYSE: CRL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRL stock methods without spending real money on the virtual paper trading platform.